Base de dados : MEDLINE
Pesquisa : C06.405.205.731 [Categoria DeCS]
Referências encontradas : 17598 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 1760 ir para página                         

  1 / 17598 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453766
[Au] Autor:Lim KJ; Lee SJ; Kim S; Lee SY; Lee MS; Park YA; Choi EJ; Lee EB; Jun HK; Cho JM; Lee S; Kwon KS; Lim BP; Jeon MS; Shin EC; Choi YS; Fudim E; Picard O; Yavzori M; Ben-Horin S; Chang SJ
[Ad] Endereço:R&D Division, Celltrion Inc., Incheon, Korea.
[Ti] Título:Comparable Immune Function Inhibition by the Infliximab Biosimilar CT-P13: Implications for Treatment of Inflammatory Bowel Disease.
[So] Source:J Crohns Colitis;11(5):593-602, 2017 May 01.
[Is] ISSN:1876-4479
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background and Aims: CT-P13 is the first biosimilar monoclonal antibody to infliximab, and was recently approved in the European Union, Japan, Korea, and USA for all six indications of infliximab. However, studies directly assessing the biologic activity of CT-P13 versus inflximab in the context of inflammatory bowel disease [IBD] are still scanty. In the present study, we aimed to compare the biological activities of CT-P13 and infliximab with specific focus on intestinal cells so as to gain insight into the potential biosimilarity of these two agents for treatment of IBD. Methods: CT-P13 and infliximab were investigated and compared by in vitro experiments for their neutralisation ability of soluble tumour necrosis factor alpha [sTNFα] and membrane-bound tumour necrosis factor alpha [mTNFα], suppression of cytokine release by reverse signalling, induction of regulatory macrophages and wound healing, and antibody-dependent cell cytotoxicity [ADCC]. Results: CT-P13 showed similar biological activities to infliximab as gauged by neutralisation of soluble TNFα, as well as blockade of apoptosis and suppression of pro-inflammatory cytokines in intestinal Caco-2 cells. Infliximab and CT-P13 equally induced apoptosis and outside-to-inside signals through transmembrane TNFα [tmTNFα]. Moreover, regulatory macrophage induction and ensuing wound healing were similarly exerted by CT-P13 and infliximab. However, neither CT-P13 nor infliximab exerted any significant ADCC of ex vivo-stimulated peripheral blood monocytes or lamina propria mononuclear cells from IBD patients. Conclusions: These findings indicate that CT-P13 and infliximab exert highly similar biological activities in intestinal cells, and further support a mechanistic comparability of these two drugs in the treatment of IBD.
[Mh] Termos MeSH primário: Anticorpos Monoclonais/farmacologia
Medicamentos Biossimilares/farmacologia
Fármacos Gastrointestinais/farmacologia
Doenças Inflamatórias Intestinais/tratamento farmacológico
Infliximab/farmacologia
Intestinos/efeitos dos fármacos
[Mh] Termos MeSH secundário: Anticorpos Monoclonais/uso terapêutico
Medicamentos Biossimilares/uso terapêutico
Células CACO-2/efeitos dos fármacos
Citocinas/metabolismo
Fármacos Gastrointestinais/uso terapêutico
Seres Humanos
Técnicas In Vitro
Infliximab/uso terapêutico
Intestinos/citologia
Intestinos/imunologia
Macrófagos/efeitos dos fármacos
Fator de Necrose Tumoral alfa/metabolismo
Cicatrização/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antibodies, Monoclonal); 0 (Biosimilar Pharmaceuticals); 0 (CT-P13); 0 (Cytokines); 0 (Gastrointestinal Agents); 0 (Tumor Necrosis Factor-alpha); B72HH48FLU (Infliximab)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/ecco-jcc/jjw183


  2 / 17598 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453767
[Au] Autor:Chu TPC; Moran GW; Card TR
[Ad] Endereço:Division of Epidemiology and Public Health, University of Nottingham, Nottingham, UK.
[Ti] Título:The Pattern of Underlying Cause of Death in Patients with Inflammatory Bowel Disease in England: A Record Linkage Study.
[So] Source:J Crohns Colitis;11(5):578-585, 2017 May 01.
[Is] ISSN:1876-4479
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background and Aims: Numerous studies have established that mortality risk in inflammatory bowel disease [IBD] patients is higher than in the general population, but the causes of death have seldom been examined. We aimed to describe causes of death in IBD. Methods: A matched cohort study using UK general practice data from Clinical Practice Research Datalink linked to death registration records. We described the distribution of causes of death among IBD patients by age at death and time since IBD diagnosis. We estimated age-specific mortality rates and hazard ratios of death in multivariable Cox proportional hazards models. Results: 20293 IBD patients were matched to 83261 non IBD patients. The mortality rate was 40% higher in IBD patients [2005 deaths] than in non IBD patients [6024 deaths] (adjusted overall hazard ratio: = 1.4, 95% confidence interval [CI]: = 1.4-1.5], with greater risk of death in Crohn's disease [hazard ratio: = 1.6, 1.5-1.7] than in ulcerative colitis [1.3, 1.3-1.4]. Causes attributable to IBD constituted 3.7% of all deaths in ulcerative colitis and 8.3% in Crohn's disease. Among IBD patients, death was less likely to be due to circulatory, respiratory or neoplastic diseases than among non IBD patients. In both IBD and non IBD patients all these causes became more clinically important with advancing age, with the commonest neoplastic cause of death being lung cancer rather than gastrointestinal cancers. Conclusions: IBD patients have an additional risk of death. Most IBD patients die of circulatory or respiratory causes, and the contribution to mortality from long-term complications of IBD is clinically less important.
[Mh] Termos MeSH primário: Causas de Morte
Doenças Inflamatórias Intestinais/mortalidade
[Mh] Termos MeSH secundário: Adolescente
Adulto
Fatores Etários
Idoso
Idoso de 80 Anos ou mais
Criança
Pré-Escolar
Colite Ulcerativa/mortalidade
Doença de Crohn/mortalidade
Atestado de Óbito
Feminino
Seres Humanos
Lactente
Recém-Nascido
Armazenamento e Recuperação da Informação
Masculino
Registros Médicos/estatística & dados numéricos
Meia-Idade
Modelos de Riscos Proporcionais
Reino Unido/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/ecco-jcc/jjw192


  3 / 17598 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453762
[Au] Autor:Melesse DY; Lix LM; Nugent Z; Targownik LE; Singh H; Blanchard JF; Bernstein CN
[Ad] Endereço:University of Manitoba Inflammatory Bowel Disease Clinical and Research Centre, University of Manitoba, Canada.
[Ti] Título:Estimates of Disease Course in Inflammatory Bowel Disease Using Administrative Data: A Population-level Study.
[So] Source:J Crohns Colitis;11(5):562-570, 2017 May 01.
[Is] ISSN:1876-4479
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background and Aims: We sought develop a predictive model of disease course in inflammatory bowel disease [IBD] using health care utilization measures from administrative health data, and to apply this model to estimate disease course at a population level over time. Methods: Study participants were IBD patients who were prospectively followed for a 1-year period between 2009 and 2010 in a Canadian clinic setting to assess their IBD disease course [i.e. remission, mild, moderate, severe]. Clinic data were linked with population-based administrative health data. A multivariable partial proportional odds model tested health care utilization measures that discriminated disease course groups. The model was applied to project the distribution of disease course for the Manitoba IBD population for 1995-2013. Results: There were 407 participants (54.3% females, 64.4% Crohn's disease [CD]) with mean age at diagnosis of 29.8 years [SD 14.9]. Forty-one per cent of participants were clinically in remission, while 14.0% had severe IBD. Mild, moderate or severe disease was associated with three or more gastroenterologist visits (odds ratio [OR] = 3.33, 95% confidence interval [CI]: 2.03-5.54) or three or more general practitioner visits [OR = 2.97, 95% CI: 1.44-6.37] with an IBD diagnosis and ≥1 radiology test [OR = 2.22, 95% CI: 1.31-3.80]. The percentages of the Manitoba IBD population in remission rose steadily from 1995 to 2013 [43.6 to 59.9%], while the percentages of individuals with mild, moderate or severe disease declined. Conclusion: This study demonstrated that health care utilization measures from administrative data can be used to predict disease course in the IBD population.
[Mh] Termos MeSH primário: Doenças Inflamatórias Intestinais/patologia
[Mh] Termos MeSH secundário: Adulto
Colite Ulcerativa/diagnóstico
Colite Ulcerativa/patologia
Doença de Crohn/diagnóstico
Doença de Crohn/patologia
Progressão da Doença
Feminino
Seres Humanos
Doenças Inflamatórias Intestinais/diagnóstico
Masculino
Prognóstico
Estudos Prospectivos
Índice de Gravidade de Doença
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/ecco-jcc/jjw201


  4 / 17598 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453761
[Au] Autor:Karreman MC; Luime JJ; Hazes JMW; Weel AEAM
[Ad] Endereço:Erasmus University Medical Center, Wytemaweg 80, Rotterdam, The Netherlands.
[Ti] Título:The Prevalence and Incidence of Axial and Peripheral Spondyloarthritis in Inflammatory Bowel Disease: A Systematic Review and Meta-analysis.
[So] Source:J Crohns Colitis;11(5):631-642, 2017 May 01.
[Is] ISSN:1876-4479
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background and Aims: Inflammatory bowel disease [IBD] is a chronic disease which affects up to 0.5% of the population. Various extraintestinal manifestations occur, among which are rheumatic manifestations, grouped together under the name spondyloarthritis. The objective of this systematic review and meta-analysis was to give a systematic overview of the prevalence and incidence of spondyloarthritis in patients with inflammatory bowel disease. Methods: We systematically searched Embase, Pubmed, OvidSP, Scopus, and Web-of-Science databases from inception to August 2016. All articles that addressed the prevalence or incidence of the different features of spondyloarthritis in adult inflammatory bowel disease patients were included. Methodological quality was assessed using a modified quality assessment tool developed for prevalence studies. Results: A total of 71 studies were included, reporting on the prevalence of sacroiliitis, ankylosing spondylitis, arthritis, enthesitis, and dactylitis. Pooled prevalences were calculated for sacroiliitis (10%; 95% confidence interval [CI] 8-12%), ankylosing spondylitis [3%; 95% CI 2-4%], and arthritis [13%; 95% CI 12-15%]. Geographical area, setting and use of different criteria contribute to the large heterogeneity. Few estimates were available for enthesitis [prevalence range from 1% to 54%] and dactylitis [prevalence range from 0% to 6%]. Only three incidence studies were identified, which report cumulative incidences from 5 to 30 years. Conclusions: Spondyloarthritis occurs in up to 13% of patients with IBD. Ankylosing spondylitis is the least common [3%] followed by sacroiliitis [10%] and peripheral arthritis [13%].
[Mh] Termos MeSH primário: Doenças Inflamatórias Intestinais/complicações
Espondilartrite/complicações
[Mh] Termos MeSH secundário: Artrite/complicações
Artrite/epidemiologia
Seres Humanos
Incidência
Prevalência
Sacroileíte/complicações
Sacroileíte/epidemiologia
Espondilartrite/epidemiologia
Espondilite Anquilosante/complicações
Espondilite Anquilosante/epidemiologia
[Pt] Tipo de publicação:JOURNAL ARTICLE; META-ANALYSIS; REVIEW
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/ecco-jcc/jjw199


  5 / 17598 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453758
[Au] Autor:Daperno M; Comberlato M; Bossa F; Armuzzi A; Biancone L; Bonanomi AG; Cosintino R; Lombardi G; Mangiarotti R; Papa A; Pica R; Grassano L; Pagana G; D'Incà R; Orlando A; Rizzello F; IGIBDEndo Group
[Ad] Endereço:Gastroenterology Unit, AO Ordine Mauriziano, Torino, TO, Italy.
[Ti] Título:Training Programs on Endoscopic Scoring Systems for Inflammatory Bowel Disease Lead to a Significant Increase in Interobserver Agreement Among Community Gastroenterologists.
[So] Source:J Crohns Colitis;11(5):556-561, 2017 May 01.
[Is] ISSN:1876-4479
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background and Aims: Endoscopic outcomes are increasingly used in clinical trials and in routine practice for inflammatory bowel disease [IBD] in order to reach more objective patient evaluations than possible using only clinical features. However, reproducibility of endoscopic scoring systems used to categorize endoscopic activity has been reported to be suboptimal. The aim of this study was to analyse the inter-rated agreement of non-dedicated gastroenterologists on IBD endoscopic scoring systems, and to explore the effects of a dedicated training programme on agreement. Methods: A total of 237 physicians attended training courses on IBD endoscopic scoring systems, and they independently scored a set of IBD endoscopic videos for ulcerative colitis [with Mayo endoscopic subscore], post-operative Crohn's disease [with Rutgeerts score] and luminal Crohn's disease (with the Simple Endoscopic Score for Crohn's Disease [SESCD] and Crohn's Endoscopic Index of Severity [CDEIS]). A second round of scoring was collected after discussion about determinants of discrepancy. Interobserver agreement was measured by means of the Fleiss' kappa [kappa] or intraclass correlation coefficient [ICC] as appropriate. Results: The inter-rater agreement increased from kappa 0.51 (95% confidence interval [95% CI] 0.48-0.55) to 0.76 [95% CI 0.72-0.79] for the Mayo endoscopic subscore, and from 0.45 [95% CI 0.40-0.50] to 0.79 [0.74-0.83] for the Rutgeerts score before and after the training programme, respectively, and both differences were significant [P < 0.0001]. The ICC was 0.77 [95% CI 0.56-0.96] for SESCD and 0.76 [0.54- 0.96] for CDEIS, respectively, with only one measurement. Discussion: The basal inter-rater agreement of inexperienced gastroenterologists focused on IBD management is moderate; however, a dedicated training programme can significantly impact on inter-rater agreement, increasing it to levels expected among expert central reviewers.
[Mh] Termos MeSH primário: Colonoscopia/educação
Gastroenterologistas/educação
Doenças Inflamatórias Intestinais/diagnóstico
[Mh] Termos MeSH secundário: Colite Ulcerativa/diagnóstico
Colite Ulcerativa/patologia
Doença de Crohn/diagnóstico
Doença de Crohn/patologia
Educação Médica Continuada/métodos
Gastroenterologistas/estatística & dados numéricos
Seres Humanos
Doenças Inflamatórias Intestinais/patologia
Variações Dependentes do Observador
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/ecco-jcc/jjw181


  6 / 17598 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453757
[Au] Autor:Bequet E; Sarter H; Fumery M; Vasseur F; Armengol-Debeir L; Pariente B; Ley D; Spyckerelle C; Coevoet H; Laberenne JE; Peyrin-Biroulet L; Savoye G; Turck D; Gower-Rousseau C; EPIMAD Group
[Ad] Endereço:Division of Gastroenterology, Hepatology and Nutrition, Department of Paediatrics, Lille University Jeanne de Flandre Children's Hospital, University of Lille, Lille, France.
[Ti] Título:Incidence and Phenotype at Diagnosis of Very-early-onset Compared with Later-onset Paediatric Inflammatory Bowel Disease: A Population-based Study [1988-2011].
[So] Source:J Crohns Colitis;11(5):519-526, 2017 May 01.
[Is] ISSN:1876-4479
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background and Aims: Very-early-onset inflammatory bowel disease [VEO-IBD] is a form of IBD that is distinct from that of children with an older onset. We compared changes over time in the incidence and phenotype at diagnosis between two groups according to age at IBD diagnosis: VEO-IBD diagnosed before the age of 6 years, and early-onset IBD [EO-IBD] diagnosed between 6 and 16 years of age. Methods: Data were obtained from a cohort enrolled in a prospective French population-based registry from 1988 to 2011. Results: Among the 1412 paediatric cases [< 17 years], 42 [3%] were VEO-IBD. In the VEO-IBD group, the incidence remained stable over the study period. In contrast, the incidence of EO-IBD increased from 4.4/105 in 1988-1990 to 9.5/105 in 2009-2011 [+116%; p < 10-4]. Crohn's disease [CD] was the most common IBD, regardless of age, but ulcerative colitis [UC] and unclassified IBD were more common in VEO-IBD cases [40% vs 26%; p = 0.04]. VEO-IBD diagnosis was most often performed in hospital [69% vs 43%; p < 10-3]. Rectal bleeding and mucous stools were more common in patients with VEO-IBD, whereas weight loss and abdominal pain were more frequent in those with EO-IBD. Regarding CD, isolated colonic disease was more common in the VEO-IBD group [39% vs 14%; p = 0.003]. Conclusions: In this large population-based cohort, the incidence of VEO-IBD was low and stable from 1988 to 2011, with a specific clinical presentation. These results suggest a probable genetic origin for VEO-IBD, whereas the increase in EO-IBD might be linked to environmental factors.
[Mh] Termos MeSH primário: Doenças Inflamatórias Intestinais/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Idade de Início
Criança
Pré-Escolar
Colite Ulcerativa/diagnóstico
Colite Ulcerativa/epidemiologia
Colite Ulcerativa/patologia
Doença de Crohn/diagnóstico
Doença de Crohn/epidemiologia
Doença de Crohn/patologia
Feminino
França/epidemiologia
Seres Humanos
Incidência
Doenças Inflamatórias Intestinais/diagnóstico
Doenças Inflamatórias Intestinais/patologia
Masculino
Fenótipo
Estudos Prospectivos
Sistema de Registros
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/ecco-jcc/jjw194


  7 / 17598 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28453756
[Au] Autor:Hovde Ø; Høivik ML; Henriksen M; Solberg IC; Småstuen MC; Moum BA
[Ad] Endereço:Department of Gastroenterology, Innlandet Hospital Trust, Gjøvik, Norway.
[Ti] Título:Malignancies in Patients with Inflammatory Bowel Disease: Results from 20 Years of Follow-up in the IBSEN Study.
[So] Source:J Crohns Colitis;11(5):571-577, 2017 May 01.
[Is] ISSN:1876-4479
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Background and Aims: Whether patients with inflammatory bowel diseases [IBDs] have increased risk of developing cancer has been debated. The aims of the study were to determine the prevalence of intestinal/extraintestinal cancers in an IBD cohort 20 years after diagnosis and to assess whether these patients had an increased cancer-specific risk compared with a matched control population. Methods: Patients with ulcerative colitis [UC] and Crohn's disease [CD] diagnosed 1990-1993 have been prospectively followed up for 20 years. Follow-up visits were carried out 1, 5, 10, and 20 years after inclusion. Data on all cancer cases, deaths, and causes of death were collected from the Cancer Registry of Norway and from the Norwegian Cause of Death Registry. Results: In all, 756 patients [519 UC and 237 CD] were diagnosed with IBD. Increased risk of cancer was seen in UC patients (hazard ratio [HR] = 1.40, 95% confidence interval [CI] 1.08-1.81, p < 0.01), but not in CD patients [HR = 1.23, 95% CI 0.80-2.03, p = 0.30]. Stratified by gender, our data revealed a statistically increased risk for all cancers only in male UC patients compared with the controls [HR = 1.51, 95% CI 1.08-2.11, p = 0.017]. In both groups breast cancer was seen more often than expected. Conclusions: Male UC patients display an increased risk of development of colorectal cancer and, also all cancers combined, compared with the controls. In both UC and CD, standardized incidence ratio for breast cancer was increased.
[Mh] Termos MeSH primário: Doenças Inflamatórias Intestinais/complicações
Neoplasias Intestinais/epidemiologia
Neoplasias/epidemiologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idoso
Idoso de 80 Anos ou mais
Causas de Morte
Criança
Pré-Escolar
Colite Ulcerativa/complicações
Doença de Crohn/complicações
Feminino
Seguimentos
Seres Humanos
Neoplasias Intestinais/etiologia
Masculino
Meia-Idade
Neoplasias/etiologia
Neoplasias/mortalidade
Noruega/epidemiologia
Sistema de Registros
Fatores de Risco
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180308
[Lr] Data última revisão:
180308
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170429
[St] Status:MEDLINE
[do] DOI:10.1093/ecco-jcc/jjw193


  8 / 17598 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29311119
[Au] Autor:Clemente JC; Manasson J; Scher JU
[Ad] Endereço:Department of Genetics and Genomic Sciences, Icahn Institute for Genomics and Multiscale Biology, Icahn School of Medicine at Mount Sinai, New York, NY, USA.
[Ti] Título:The role of the gut microbiome in systemic inflammatory disease.
[So] Source:BMJ;360:j5145, 2018 01 08.
[Is] ISSN:1756-1833
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:The role of the gut microbiome in models of inflammatory and autoimmune disease is now well characterized. Renewed interest in the human microbiome and its metabolites, as well as notable advances in host mucosal immunology, has opened multiple avenues of research to potentially modulate inflammatory responses. The complexity and interdependence of these diet-microbe-metabolite-host interactions are rapidly being unraveled. Importantly, most of the progress in the field comes from new knowledge about the functional properties of these microorganisms in physiology and their effect in mucosal immunity and distal inflammation. This review summarizes the preclinical and clinical evidence on how dietary, probiotic, prebiotic, and microbiome based therapeutics affect our understanding of wellness and disease, particularly in autoimmunity.
[Mh] Termos MeSH primário: Doenças Autoimunes/microbiologia
Comportamento Alimentar/fisiologia
Microbioma Gastrointestinal/imunologia
Inflamação/microbiologia
Doenças Inflamatórias Intestinais/microbiologia
Membrana Mucosa/microbiologia
[Mh] Termos MeSH secundário: Doenças Autoimunes/imunologia
Transplante de Microbiota Fecal/métodos
Microbioma Gastrointestinal/fisiologia
Seres Humanos
Inflamação/imunologia
Doenças Inflamatórias Intestinais/imunologia
Doenças Inflamatórias Intestinais/patologia
Microbiota
Membrana Mucosa/imunologia
Prebióticos
Probióticos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Prebiotics)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180305
[Lr] Data última revisão:
180305
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1136/bmj.j5145


  9 / 17598 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29390318
[Au] Autor:Hench J; Cathomas G; Dettmer MS
[Ad] Endereço:Institute of Pathology, Cantonal Hospital Baselland, Liestal.
[Ti] Título:Hymenolepis nana: A case report of a perfect IBD camouflage warrior.
[So] Source:Medicine (Baltimore);96(50):e9146, 2017 Dec.
[Is] ISSN:1536-5964
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:RATIONALE: There is evidence that parasitic helminths can ameliorate colitis in animal models and humans. Although infections with Hymenolepis sp. are clinically benign, the immunomodulatory interactions between host and parasite are largely unknown. PATIENT CONCERNS: In this study we examined the intestinal mucosa of an adult asymptomatic patient harboring adult and larval dwarf tapeworms (Hymenolepis nana) who underwent surgery for an unrelated reason. INTERVENTIONS: Routine histology and immunohistochemistry were performed to characterize the host's response to the parasite. Parasitic DNA was sequenced to identify the tapeworm species. DIAGNOSES: Morphological and immunohistochemical studies showed a nearly complete absence of an anti-parasite host immune response. The outer surface of the parasite also showed prominent cross-reactivity with various tested leukocyte antigens. Our findings closely resemble experimentally obtained data from the H. diminuta-infected rat at the state of persistent colonization. OUTCOMES: Cross-reactivity of parasite-borne molecules with anti-human-leukocyte antibodies indicates a potential functional role in active modulation of the host's immune response. LESSIONS: We believe that better understanding of the host-cestode interaction will certainly extend our knowledge on auto-aggressive disorders such as inflammatory bowel disease and might provide potential treatment options.
[Mh] Termos MeSH primário: Himenolepíase/diagnóstico
Hymenolepis nana
Doenças Inflamatórias Intestinais/parasitologia
Divertículo Ileal/parasitologia
[Mh] Termos MeSH secundário: Adulto
Animais
Apendicite/cirurgia
Diagnóstico Diferencial
Feminino
Seres Humanos
Achados Incidentais
[Pt] Tipo de publicação:CASE REPORTS; JOURNAL ARTICLE
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180203
[St] Status:MEDLINE
[do] DOI:10.1097/MD.0000000000009146


  10 / 17598 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29447693
[Au] Autor:Johnson AMF; DePaolo RW
[Ad] Endereço:Division of Gastroenterology, Department of Medicine, University of Washington, Seattle, WA, USA.
[Ti] Título:Infectious Scarring: Setting the Trigger for Intestinal Inflammation.
[So] Source:Cell Host Microbe;23(2):154-156, 2018 02 14.
[Is] ISSN:1934-6069
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The initiating factors that trigger inflammatory bowel disease (IBD) are poorly understood. In a recent paper, Yang et al. (2017) demonstrate that IBD-like syndrome in mice can develop as a consequence of recurrent pathogen infection. Pathogenic triggering of inflammatory disease is a re-emerging concept that has significant therapeutic implications.
[Mh] Termos MeSH primário: Cicatriz
Inflamação
[Mh] Termos MeSH secundário: Animais
Doenças Inflamatórias Intestinais
Intestinos
Camundongos
[Pt] Tipo de publicação:JOURNAL ARTICLE; COMMENT
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180227
[Lr] Data última revisão:
180227
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180216
[St] Status:MEDLINE



página 1 de 1760 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde